Severe adverse reactions to infliximab therapy are common in young children with inflammatory bowel disease

Acta Paediatrica, International Journal of Paediatrics

Volumn 96, Issue 1, 2007, Pages 128-130

  Kolho, K L ^a,c   Ruuska, T ^b   Savilahti, E ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Adverse effect; Croh s disease; TNF alpha antagonist; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; GLUCOCORTICOID; INFLIXIMAB; MESALAZINE; PREDNISOLONE;

ABSCESS; ADOLESCENT; ADULT; AGE DISTRIBUTION; ANAPHYLAXIS; ARTICLE; BLOOD PRESSURE; BRAIN DAMAGE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSPNEA; ENTERITIS; FATIGUE; FEMALE; HUMAN; INFLUENZA; MALE; NAUSEA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SEPTICEMIA; SIDE EFFECT; THORAX PAIN; ULCERATIVE COLITIS; URTICARIA; VERTIGO;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; RETROSPECTIVE STUDIES;

EID: 33847221117     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2007.00042.x     Document Type: Article

References (12)

1. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251-9.
2. Wewer V, Riis L, Vind I, Husby S, Munkholm P, Paerregaard A. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr 2006; 42: 40-5.
3. Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004; 39: 265-9.
4. Cezard J-P, Nouaili N, Talbotec C, Hugot J-P, Gobert J-G, Schmitz J, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe Pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003; 36: 632-6.
5. Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory disease center. Am J Gastroenterol 2003; 98: 104-11.
6. Jacobstein DA, Markowitz JE, Kirschner BS, Cohen G, Stanley A, Gold BD, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005; 442-6.
7. Colombel J-F, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.
8. Lamireau Th, Cézard J-P, Dabadie A, Goulet O, Lachauz A, Turck D, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004; 10: 745-50.
9. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004; 38: 502-8.
10. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17: 75-84.
11. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn' disease. NEJM 2003; 348: 601-8.
12. Thomas CW Jr, Weinshenker BG, Sandborn WJ. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004; 10: 28-31.